



Press release

7th December 2015

Fidelta and e-Therapeutics plc announce an integrated drug discovery deal

Zagreb, Croatia, 7th December 2015 – Fidelta, a Galapagos company, announced today the start of a collaboration with e-Therapeutics, whereby Fidelta will provide medicinal chemistry, DMPK and pharmacology services to advance e-Therapeutics' drug discovery programs.

Phil Dudfield, Managing Director, Fidelta commented, "We are excited to be working together with e-Therapeutics on integrated projects with the aim of optimizing potent e-Therapeutics lead molecules to develop clinical candidates using Fidelta's expertise.

Professor Malcolm Young, CEO of e-Therapeutics, said "We are delighted to be working together with Fidelta to advance our projects through chemistry optimization. Fidelta has already proved itself a reliable partner on our programs, and we are pleased to broaden the activities being undertaken."

About Fidelta

Fidelta, a wholly-owned subsidiary of Galapagos N.V., is a fee-for-service, collaborative drug discovery organization that combines expertise in the areas of chemistry, pharmacology, ADME, pharmacokinetics and toxicology. Fidelta offers fully integrated services, as well as flexible stand-alone solutions for projects in discovery and early pre-clinical development. Fidelta has developed a new macrocyclic drug discovery platform, FideltaMacro.TM

Fidelta's objective is to deliver efficacious, safe and differentiated pre-clinical candidates for its clients. For more information, visit www.fidelta.eu

About eTherapeutics

e-Therapeutics (LSE AIM: ETX.L) is a drug discovery and development company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.

The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology and addressing drug resistance in targeted cancer therapies. The platform is yielding multiple, highly potent, selective and diverse molecules at much higher yields than is reported for conventional drug discovery.

e-Therapeutics is also advancing its most promising programmes through clinical trials. There is a phase IIb clinical stage drug candidate for major depressive disorder, ETS6103; and a phase Ib clinical stage candidate in hepatocellular and pancreatic cancer, ETS2101. The Company also has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNF α ; ETS2400 and Hedgehog pathway inhibition; and ETS5200, a broad-spectrum antiviral program.

The Company is fully funded to advance its existing development programmes in cancer and depression and a further programme from its discovery platform. It is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.

More information:

Fidelta d.o.o.

Adrijana Vinter, Business Development Director

Tel: +385 1 8886395

fidelta@glpg.com

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Fidelta, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Fidelta expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.